Fluoxetine - delayed treatment
Phase 2Small molecule
Fluoxetine - delayed treatment is one of 3 small molecule programs targeting OCD. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2 competitors in OCD
#DrugCompanyPhaseTrials
1Robitussin
PfizerPhase 2
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Fluoxetine - delayed treatment
YYale University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- YYale University